FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer
GSK's Jemperli (dostarlimab-gxly) received FDA accelerated approval for stage II/III MSI-H/dMMR locally advanced rectal cancer. The PD-1 inhibitor is the first immunotherapy for this indication, based on AZUR-1 trial data showing 47% 12-month response by independent review. Approval is conditional on confirmatory trials. GSK's Tony Wood highlighted the shift from traditional treatments to personalized care.
How this was made

The 30-second read
Why it matters
The approval creates a new revenue stream and may boost GSK's oncology portfolio valuation.
Market read
First FDA approval for this indication; likely to drive short‑term GSK stock upside and affect biotech sector sentiment.
What to watch
Conditional approval and reliance on single‑arm data may limit payer reimbursement and long‑term uptake.
Background
GSK announced FDA accelerated approval of its PD‑1 inhibitor Jemperli for a niche rectal cancer indication.
Ticker impact
FDA granted accelerated approval to Jemperli (dostarlimab-gxly) for MSI-H/dMMR locally advanced rectal cancer.
upward pressure as market prices in the new indication and potential sales growth
First report of FDA approval; biotech stocks typically rally on regulatory wins, especially for a first‑in‑class immunotherapy.
Market effects
May lift other oncology biotech peers as investors reassess MSI-H/dMMR market potential.
Positive for UK‑listed pharma sector where GSK is a major component.
Adds to global oncology pipeline momentum, could influence biotech indices worldwide.
Counterpoint
If the confirmatory trials fail to show durable responses, the initial rally could reverse.
Key entities
- companyGSK
British‑American pharmaceutical giant receiving FDA approval.
- drugJemperli (dostarlimab-gxly)
PD‑1 inhibitor now approved for MSI‑H/dMMR rectal cancer.




